Jack Anders - 01 Mar 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Mar 2026, 21:07:14 UTC
Prior SEC filing
09 Jan 2026
Next SEC filing
19 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jack Anders

Key filing fact

Jack Anders filed Form 4 for Revolution Medicines, Inc. (RVMD) on 03 Mar 2026.

Key facts

  • This page summarizes Jack Anders's Form 4 filing for Revolution Medicines, Inc. (RVMD).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 03 Mar 2026, 21:07.

Change

  • Previous filing in this sequence was filed on 09 Jan 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001800668 Primary reporting owner

Anders Jack

Relationship
Chief Financial Officer
Address
C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
Signature
/s/ Jack Anders
Signature date
03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Award

Transaction value
$0
Shares
+20,200
Change %
+19%
Price
$0.000000
Shares after
128,265
Date
01 Mar 2026
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RVMD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+45,400
Change %
Price
$0.000000
Shares after
45,400
Date
01 Mar 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
45,400
Exercise price
$102.02
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes 62,538 restricted stock units.

Footnote F2

One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .